Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Morepen Laboratories to expand domestic salesforce by 1,000 as part of formulations growth plan
Expansion targets ₹1,000 crore finished dosages business by 2030, aligning with India's vision for affordable and accessible…
OneSource specialty pharma secures ANVISA GMP certification for Bengaluru unit 2 facility
Approval enables OneSource to supply drug-device combinations including GLP-1s to Brazil, ahead of Semaglutide generics entering…
N-FIS was developed to address a critical challenge in healthcare—needle phobia
Integri Medical has launched a needle-free injection system (N-FIS) to address needle phobia and enhance patient convenience.In…
Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for…
AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…
Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE
The approval marks Biocon Biologics’ seventh biosimilar clearance in the US, expanding its oncology portfolio in one of the…
Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no…
Shilpa Medicare's Unit-2 API facility in Raichur, India passes March 2025 FDA audit without Form 483 observations, reinforcing…
Logistics4Pharma expands customs services with transit document management and bonded storage near…
Frankfurt-based Logistics4Pharma introduces a full-service customs portfolio, enhancing controlled storage and transit solutions…
FOPE and PharmaState Academy conduct session on sterile drug manufacturing under Revised Schedule M
Session 18 of the PULSE initiative focuses on regulatory compliance, operational standards, and technical readiness in sterile…
Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case
Settlement resolves allegations Jazz delayed generic Xyrem launch, driving up costs for health plans and patients
Large pharma drug licensing from China reaches record high at 28 per cent in 2024, reveals…
Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…